Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 8/20 | 0.57 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.57 |
| ▸ | CDK2 | P24941 | 5/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.42 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129642 | 0.82 | CDK1 (0.68) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL27220347 | 0.81 | CDK1 (0.42) | CDK1CCNB1CCNE1CDK2HSP90AA1 | |
| SCHEMBL790146 | 0.80 | CDK1 (0.46) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL1898082 | 0.79 | HSP90AB1 (0.41) | CDK1CCNB1CCNE1CDK2HSP90AA1 | |
| SCHEMBL17226007 | 0.79 | CDK1 (0.55) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL764036 | 0.79 | CDK1 (0.59) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| 9-Methylguanine SCHEMBL2787045 | 0.79 | CDK1 (0.59) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL25876344 | 0.77 | CDK1 (0.66) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL16481592 | 0.77 | CDK1 (0.43) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL24021902 | 0.77 | CDK1 (0.53) | CDK1CCNB1CCNE1CDK2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4043473-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMERS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-08-17 | — | — | EP | disclosed |
| EP-3194411-B1 | NUCLEOTIDE ANALOGS | UNIV CALIFORNIA (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2016044281-A1 | NUCLEOTIDE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20120115136-A1 | PNA DIAGNOSTIC USE | PNA Patent Owners (a/k/a CIG) (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115136-A1 | PNA DIAGNOSTIC USE | RNASE1, NCL, PABPC4 | CDK1 4451/4885CCNB1 3079/4885CCNE1 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.